Jordan L Smith1,2, Tomás C Rodríguez1,2, Haiwei Mou3, Suet-Yan Kwan1, Henry Pratt2,4, Xiao-Ou Zhang4, Yueying Cao1, Shunqing Liang1, Deniz M Ozata1, Tianxiong Yu5, Qiangzong Yin6, Max Hazeltine7, Zhiping Weng4, Erik J Sontheimer1,8,9, Wen Xue1,8,9,10. 1. RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA. 2. Medical Scientist Training Program, University of Massachusetts Medical School, Worcester, MA. 3. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 4. Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA. 5. Department of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai, China. 6. Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA. 7. Department of Surgery, University of Massachusetts Medical School, Worcester, MA. 8. Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA. 9. Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA. 10. Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA.
Abstract
BACKGROUND AND AIMS: Despite surgical and chemotherapeutic advances, the 5-year survival rate for stage IV hepatoblastoma (HB), the predominant pediatric liver tumor, remains at 27%. Yes-associated protein 1 (YAP1) and β-catenin co-activation occurs in 80% of children's HB; however, a lack of conditional genetic models precludes tumor maintenance exploration. Thus, the need for a targeted therapy remains unmet. Given the predominance of YAP1 and β-catenin activation in HB, we sought to evaluate YAP1 as a therapeutic target in HB. APPROACH AND RESULTS: We engineered the conditional HB murine model using hydrodynamic injection to deliver transposon plasmids encoding inducible YAP1S127A , constitutive β-cateninDelN90 , and a luciferase reporter to murine liver. Tumor regression was evaluated using bioluminescent imaging, tumor landscape characterized using RNA and ATAC sequencing, and DNA footprinting. Here we show that YAP1S127A withdrawal mediates more than 90% tumor regression with survival for 230+ days in mice. YAP1S127A withdrawal promotes apoptosis in a subset of tumor cells, and in remaining cells induces a cell fate switch that drives therapeutic differentiation of HB tumors into Ki-67-negative hepatocyte-like HB cells ("HbHeps") with hepatocyte-like morphology and mature hepatocyte gene expression. YAP1S127A withdrawal drives the formation of hbHeps by modulating liver differentiation transcription factor occupancy. Indeed, tumor-derived hbHeps, consistent with their reprogrammed transcriptional landscape, regain partial hepatocyte function and rescue liver damage in mice. CONCLUSIONS: YAP1S127A withdrawal, without silencing oncogenic β-catenin, significantly regresses hepatoblastoma, providing in vivo data to support YAP1 as a therapeutic target for HB. YAP1S127A withdrawal alone sufficiently drives long-term regression in HB, as it promotes cell death in a subset of tumor cells and modulates transcription factor occupancy to reverse the fate of residual tumor cells to mimic functional hepatocytes.
BACKGROUND AND AIMS: Despite surgical and chemotherapeutic advances, the 5-year survival rate for stage IV hepatoblastoma (HB), the predominant pediatric liver tumor, remains at 27%. Yes-associated protein 1 (YAP1) and β-catenin co-activation occurs in 80% of children's HB; however, a lack of conditional genetic models precludes tumor maintenance exploration. Thus, the need for a targeted therapy remains unmet. Given the predominance of YAP1 and β-catenin activation in HB, we sought to evaluate YAP1 as a therapeutic target in HB. APPROACH AND RESULTS: We engineered the conditional HB murine model using hydrodynamic injection to deliver transposon plasmids encoding inducible YAP1S127A , constitutive β-cateninDelN90 , and a luciferase reporter to murine liver. Tumor regression was evaluated using bioluminescent imaging, tumor landscape characterized using RNA and ATAC sequencing, and DNA footprinting. Here we show that YAP1S127A withdrawal mediates more than 90% tumor regression with survival for 230+ days in mice. YAP1S127A withdrawal promotes apoptosis in a subset of tumor cells, and in remaining cells induces a cell fate switch that drives therapeutic differentiation of HB tumors into Ki-67-negative hepatocyte-like HB cells ("HbHeps") with hepatocyte-like morphology and mature hepatocyte gene expression. YAP1S127A withdrawal drives the formation of hbHeps by modulating liver differentiation transcription factor occupancy. Indeed, tumor-derived hbHeps, consistent with their reprogrammed transcriptional landscape, regain partial hepatocyte function and rescue liver damage in mice. CONCLUSIONS: YAP1S127A withdrawal, without silencing oncogenic β-catenin, significantly regresses hepatoblastoma, providing in vivo data to support YAP1 as a therapeutic target for HB. YAP1S127A withdrawal alone sufficiently drives long-term regression in HB, as it promotes cell death in a subset of tumor cells and modulates transcription factor occupancy to reverse the fate of residual tumor cells to mimic functional hepatocytes.
Authors: J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Julien Fitamant; Filippos Kottakis; Samira Benhamouche; Helen S Tian; Nicolas Chuvin; Christine A Parachoniak; Julia M Nagle; Rushika M Perera; Marjorie Lapouge; Vikram Deshpande; Andrew X Zhu; Albert Lai; Bosun Min; Yujin Hoshida; Joseph Avruch; Daniela Sia; Genís Campreciós; Andrea I McClatchey; Josep M Llovet; David Morrissey; Lakshmi Raj; Nabeel Bardeesy Journal: Cell Rep Date: 2015-03-12 Impact factor: 9.423
Authors: Meritxell Huch; Craig Dorrell; Sylvia F Boj; Johan H van Es; Vivian S W Li; Marc van de Wetering; Toshiro Sato; Karien Hamer; Nobuo Sasaki; Milton J Finegold; Annelise Haft; Robert G Vries; Markus Grompe; Hans Clevers Journal: Nature Date: 2013-01-27 Impact factor: 49.962
Authors: Katarzyna B Hooks; Jérôme Audoux; Helena Fazli; Sarah Lesjean; Tony Ernault; Nathalie Dugot-Senant; Thierry Leste-Lasserre; Martin Hagedorn; Benoit Rousseau; Coralie Danet; Sophie Branchereau; Laurence Brugières; Sophie Taque; Catherine Guettier; Monique Fabre; Anne Rullier; Marie-Annick Buendia; Thérèse Commes; Christophe F Grosset; Anne-Aurélie Raymond Journal: Hepatology Date: 2018-05-14 Impact factor: 17.425
Authors: Aziz Khan; Oriol Fornes; Arnaud Stigliani; Marius Gheorghe; Jaime A Castro-Mondragon; Robin van der Lee; Adrien Bessy; Jeanne Chèneby; Shubhada R Kulkarni; Ge Tan; Damir Baranasic; David J Arenillas; Albin Sandelin; Klaas Vandepoele; Boris Lenhard; Benoît Ballester; Wyeth W Wasserman; François Parcy; Anthony Mathelier Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971